Agilent Technologies, Inc. (A) Income Statement Analysis

See more : Longchen Paper & Packaging Co., Ltd. (1909.TW) Income Statement Analysis – Financial Results

Complete financial analysis of Agilent Technologies, Inc. (A) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Agilent Technologies, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

Future Health ESG Corp. (FHLTU) Income Statement Analysis – Financial Results
The Yokohama Rubber Co., Ltd. (5101.T) Income Statement Analysis – Financial Results
Tien Li Offshore Wind Technology Co., Ltd. (6793.TWO) Income Statement Analysis – Financial Results
Daeduck Co.,Ltd. (008060.KS) Income Statement Analysis – Financial Results
Linius Technologies Limited (LNNTF) Income Statement Analysis – Financial Results

Agilent Technologies, Inc. (A)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.agilent.com

About Agilent Technologies, Inc.

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998
Revenue	6.51B	6.83B	6.85B	6.32B	5.34B	5.16B	4.91B	4.47B	4.20B	4.04B	6.98B	6.78B	6.86B	6.62B	5.44B	4.48B	5.77B	5.42B	4.97B	5.14B	7.18B	6.06B	6.01B	8.40B	10.77B	8.33B	7.95B
Cost of Revenue	2.98B	3.37B	3.13B	2.91B	2.50B	2.36B	2.23B	2.06B	2.01B	2.00B	3.39B	3.25B	3.25B	3.09B	2.51B	2.19B	2.58B	2.45B	2.32B	2.62B	4.06B	3.76B	3.69B	5.17B	5.52B	4.39B	4.04B
Gross Profit	3.54B	3.47B	3.72B	3.41B	2.84B	2.81B	2.69B	2.41B	2.20B	2.04B	3.59B	3.54B	3.60B	3.53B	2.93B	2.29B	3.20B	2.97B	2.66B	2.52B	3.12B	2.29B	2.32B	3.23B	5.25B	3.94B	3.92B
Gross Profit Ratio	54.30%	50.71%	54.35%	53.92%	53.14%	54.33%	54.68%	53.87%	52.28%	50.54%	51.47%	52.12%	52.55%	53.35%	53.82%	51.15%	55.35%	54.78%	53.45%	49.08%	43.49%	37.88%	38.54%	38.47%	48.74%	47.33%	49.26%
Research & Development	479.00M	481.00M	467.00M	441.00M	495.00M	404.00M	385.00M	339.00M	329.00M	330.00M	719.00M	704.00M	668.00M	649.00M	612.00M	642.00M	704.00M	685.00M	655.00M	738.00M	933.00M	1.05B	1.17B	1.35B	1.26B	997.00M	948.00M
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	1.37B	1.23B	1.25B	1.19B	2.04B	1.88B	1.82B	1.81B	1.75B	1.60B	1.70B	1.70B	1.66B	1.60B	1.80B	1.97B	2.75B	2.66B	2.94B	2.21B	2.05B
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	1.57B	1.63B	1.64B	1.62B	1.50B	1.46B	1.37B	1.23B	1.25B	1.19B	2.04B	1.88B	1.82B	1.81B	1.75B	1.60B	1.70B	1.70B	1.66B	1.60B	1.80B	1.97B	2.75B	2.66B	2.94B	2.21B	2.05B
Other Expenses	0.00	0.00	-39.00M	92.00M	66.00M	16.00M	55.00M	19.00M	-10.00M	17.00M	-81.00M	8.00M	0.00	0.00	0.00	0.00	0.00	0.00	-121.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	477.00M
Operating Expenses	2.05B	2.12B	2.10B	2.06B	1.99B	1.86B	1.76B	1.57B	1.58B	1.52B	2.76B	2.58B	2.49B	2.46B	2.36B	2.25B	2.40B	2.39B	2.19B	2.34B	2.74B	3.02B	3.92B	4.01B	4.20B	3.20B	3.48B
Cost & Expenses	5.02B	5.48B	5.23B	4.97B	4.49B	4.22B	3.99B	3.63B	3.59B	3.52B	6.15B	5.83B	5.74B	5.54B	4.88B	4.43B	4.98B	4.84B	4.51B	4.96B	6.80B	6.78B	7.62B	9.17B	9.72B	7.59B	7.51B
Interest Income	80.00M	51.00M	9.00M	2.00M	8.00M	36.00M	38.00M	22.00M	11.00M	7.00M	9.00M	7.00M	9.00M	14.00M	20.00M	29.00M	113.00M	172.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	-96.00M	95.00M	84.00M	81.00M	78.00M	74.00M	75.00M	79.00M	72.00M	66.00M	113.00M	107.00M	101.00M	86.00M	96.00M	88.00M	123.00M	91.00M	0.00	0.00	0.00	198.00M	0.00	0.00	0.00	0.00	46.00M
Depreciation & Amortization	0.00	271.00M	317.00M	321.00M	308.00M	238.00M	210.00M	214.00M	247.00M	253.00M	383.00M	372.00M	301.00M	253.00M	202.00M	162.00M	201.00M	191.00M	170.00M	186.00M	292.00M	362.00M	735.00M	734.00M	495.00M	475.00M	477.00M
EBITDA	1.49B	1.70B	1.99B	1.73B	1.35B	1.28B	1.18B	1.10B	863.00M	778.00M	648.00M	758.00M	1.45B	1.40B	788.00M	257.00M	1.14B	775.00M	634.00M	396.00M	275.00M	-358.00M	-872.00M	-345.00M	1.38B	862.00M	919.00M
EBITDA Ratio	22.86%	24.92%	27.82%	27.88%	23.00%	23.84%	25.05%	24.46%	20.51%	19.79%	16.36%	19.73%	20.84%	20.23%	14.47%	5.31%	16.73%	14.21%	9.17%	5.72%	8.69%	-6.57%	-15.51%	-4.11%	13.34%	14.04%	11.56%
Operating Income	1.49B	1.35B	1.62B	1.35B	846.00M	941.00M	928.00M	841.00M	615.00M	522.00M	831.00M	951.00M	1.12B	1.07B	566.00M	47.00M	795.00M	584.00M	464.00M	181.00M	386.00M	-725.00M	-1.61B	-778.00M	1.05B	741.00M	442.00M
Operating Income Ratio	22.86%	19.76%	23.63%	21.32%	15.85%	18.23%	18.88%	18.81%	14.64%	12.93%	11.90%	14.02%	16.32%	16.19%	10.40%	1.05%	13.77%	10.77%	9.33%	3.52%	5.38%	-11.97%	-26.74%	-9.27%	9.77%	8.89%	5.56%
Total Other Income/Expenses	33.00M	-11.00M	-114.00M	13.00M	-4.00M	-22.00M	42.00M	-38.00M	-71.00M	-42.00M	-190.00M	473.00M	-76.00M	-39.00M	126.00M	-40.00M	20.00M	86.00M	163.00M	85.00M	117.00M	30.00M	60.00M	301.00M	111.00M	46.00M	-46.00M
Income Before Tax	1.52B	1.34B	1.50B	1.36B	842.00M	919.00M	946.00M	803.00M	544.00M	480.00M	646.00M	859.00M	1.04B	1.03B	692.00M	7.00M	815.00M	670.00M	627.00M	254.00M	440.00M	-690.00M	-1.55B	-477.00M	1.16B	787.00M	396.00M
Income Before Tax Ratio	23.36%	19.60%	21.96%	21.52%	15.77%	17.80%	19.25%	17.96%	12.95%	11.89%	9.25%	12.67%	15.21%	15.60%	12.71%	0.16%	14.11%	12.36%	12.61%	4.94%	6.13%	-11.39%	-25.74%	-5.68%	10.80%	9.45%	4.98%
Income Tax Expense	232.00M	99.00M	250.00M	150.00M	123.00M	-152.00M	630.00M	119.00M	84.00M	45.00M	149.00M	135.00M	-110.00M	20.00M	68.00M	38.00M	122.00M	32.00M	91.00M	155.00M	91.00M	1.10B	-525.00M	-71.00M	407.00M	275.00M	139.00M
Net Income	1.29B	1.24B	1.25B	1.21B	719.00M	1.07B	316.00M	684.00M	460.00M	398.00M	497.00M	724.00M	1.15B	1.01B	624.00M	-31.00M	693.00M	638.00M	3.31B	327.00M	349.00M	-2.06B	-1.03B	168.00M	757.00M	512.00M	257.00M
Net Income Ratio	19.80%	18.15%	18.31%	19.15%	13.47%	20.74%	6.43%	15.30%	10.95%	9.86%	7.12%	10.68%	16.81%	15.30%	11.46%	-0.69%	12.00%	11.77%	66.50%	6.36%	4.86%	-33.98%	-17.17%	2.00%	7.03%	6.15%	3.23%
EPS	4.44	4.22	4.19	3.98	2.33	3.41	0.98	2.12	1.41	1.20	1.49	2.12	3.31	2.92	1.80	-0.09	1.91	1.62	7.67	0.66	0.76	-4.35	-2.22	0.38	1.68	1.35	0.58
EPS Diluted	4.43	4.19	4.18	3.94	2.30	3.37	0.97	2.10	1.40	1.19	1.47	2.10	3.27	2.85	1.77	-0.09	1.87	1.57	7.50	0.65	0.75	-4.35	-2.22	0.38	1.66	1.35	0.56
Weighted Avg Shares Out	290.00M	294.00M	299.00M	304.00M	309.00M	314.00M	321.00M	322.00M	326.00M	333.00M	333.00M	341.00M	348.00M	347.00M	347.00M	346.00M	363.00M	394.00M	431.00M	494.00M	483.00M	473.00M	465.00M	458.00M	449.00M	380.00M	443.10M
Weighted Avg Shares Out (Dil)	291.00M	296.00M	300.00M	307.00M	312.00M	318.00M	325.00M	326.00M	329.00M	335.00M	338.00M	345.00M	353.00M	355.00M	353.00M	346.00M	371.00M	406.00M	441.00M	500.00M	490.00M	473.00M	465.00M	458.00M	455.00M	457.50M	458.93M

Agilent (A) Boosts LSAG Segment With J&W 5Q GC/MS Columns

August 20, 2024zacks.com

Agilent Technologies (A) launches J&W 5Q GC/MS Columns to address the growing demand for modern laboratories.

Agilent (A) Set to Report Q3 Earnings: What's in the Offing?

August 19, 2024zacks.com

Agilent's (A) fiscal third-quarter results are likely to reflect strength in the ACG and DGG segments despite the weak LSAG segment.

Wall Street's Insights Into Key Metrics Ahead of Agilent (A) Q3 Earnings

August 16, 2024zacks.com

Beyond analysts' top -and-bottom-line estimates for Agilent (A), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2024.

Analysts Estimate Agilent Technologies (A) to Report a Decline in Earnings: What to Look Out for

August 14, 2024zacks.com

Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agilent Receives FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy

August 2, 2024businesswire.com

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc., (NYSE: A) today announced that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with synovial sarcoma who may be...